Ascendis Pharma A/S
NASDAQ:ASND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascendis Pharma A/S
NASDAQ:ASND
|
DK |
|
Crane NXT Co
F:P8Q
|
US |
|
Tokyo Century Corp
F:59O
|
JP |
|
Arvind Ltd
NSE:ARVIND
|
IN |
|
Q
|
Quinstreet Inc
SWB:5Q8
|
US |
|
Lintec Corp
F:57T
|
JP |
|
Q
|
Quinstreet Inc
XBER:5Q8
|
US |
|
Taboola.com Ltd
F:1FY
|
US |
|
American International Group Inc
F:AINN
|
US |
|
Repay Holdings Corp
F:0YR
|
US |
|
B.P. Marsh & Partners PLC
LSE:BPM
|
UK |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
US |
|
S
|
SF Real Estate Investment Trust
F:8ET
|
HK |
|
B
|
Basf Se
BMV:BASN
|
DE |
|
M
|
Moelis & Co
F:17M
|
US |
|
C
|
Canadian Natural Resources Ltd
F:CRC
|
CA |
|
A
|
Andlauer Healthcare Group Inc
F:3LT
|
CA |
|
Q
|
Quinstreet Inc
F:5Q8
|
US |
|
C
|
Canadian Natural Resources Ltd
XMUN:CRC
|
CA |
|
A
|
Ascendis Pharma A/S
F:A71
|
DK |
Bankruptcy Probability
Ascendis Pharma A/S's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Ascendis Pharma A/S Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DK |
|
Ascendis Pharma A/S
NASDAQ:ASND
|
17.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
459.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
240.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
187.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
141.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
87.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
55.9B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
83.6B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Ascendis Pharma A/S's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Ascendis Pharma A/S has total debt of 384.6m EUR. This includes both short-term (0 EUR) and long-term (384.6m EUR) debt.
You can find a full breakdown on its Balance Sheet.
